Bortezomib Consolidation Trial
The aim of this trial is to determine whether bortezomib improves response and delays progression for multiple myeloma patients after high dose therapy and autologous stem cell transplant. It will also assess the effect of bortezomib treatment on patient bone health.
Multiple Myeloma
DRUG: Bortezomib
Change in Disease response, Disease response prior to consolidation with bortezomib will be compared with disease response at 6 and 12 months post ASCT., At 6 and 12 months after ASCT consolidated by bortezomib therapy|Number of patients with adverse events, The number and percentage of patients who experience adverse events related to bortezomib treatment will be summarised for patients who received bortezomib consolidation after ASCT, Up to 8 months after treatment start
assess effect of bortezomib consolidation on bone health, Summary of changes from baseline, after cycle 1,2 and 3 of bortezomib treatment and at the end of treatment for markers of bone formation and resorption, At 1, 2, 3 and 9 months after start of treatment|assess the effect of bortezomib consolidation on Minimal Residue Disease status, At 6 and 12 months post ASCT|determine progression free survival, At 2 years post ASCT|evaluate the quality of life for patients receiving bortezomib consolidation, Up to 8 months after treatment start
The aim of this trial is to determine whether bortezomib improves response and delays progression for multiple myeloma patients after high dose therapy and autologous stem cell transplant. It will also assess the effect of bortezomib treatment on patient bone health.